EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study

Jinyi Yuan, Yehuda Carmeli, José Miguel Cisneros, George L Daikos, Mical Paul, Yongjie Zhao, Jinfu Xu, Ying Ma, Wenjuan Xu, Michele Wible, Joanne Leaney, Heidi Leister-Tebbe und 3 weitere

Infectious Diseases and Therapy · 12.11.2026

DOI: 10.1007/s40121-026-01477-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 12.11.2026. Verfasst von Jinyi Yuan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Dev…, Innovative Medicines Initiative Joint Undertaking, European Union Seventh Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The phase 3 REVISIT trial evaluated aztreonam-avibactam versus meropenem ± colistin for complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), or ventilator-associated pneumonia (VAP). This descriptive post hoc analysis explored efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP. METHODS: This post hoc analysis included patients who received colistin plus meropenem (all with baseline Acute Physiology and Chronic Health Evaluation II [APACHE II] scores ≥ 8) and patients who received aztreonam-avibactam with baseline APACHE II scores ≥ 8, for comparable baseline severity. The primary efficacy endpoint was adjudicated clinical cure rate at the test-of-cure (TOC) visit in the intent-to-treat (ITT) and clinically evaluable (CE) analysis sets. Secondary endpoints included clinical cure rate at TOC by infection type, favorable microbiological response at TOC, 28-day mortality, and safety. Efficacy and safety outcomes were compared descriptively. RESULTS: Overall, we included 186 patients in the ITT population (aztreonam-avibactam, n = 160; colistin plus meropenem, n = 26). Clinical cure rates (95% CI) were 63.1% (55.5-70.3) and 53.8% (35.1-71.8) for aztreonam-avibactam and colistin plus meropenem, respectively (ITT). Results were similar in the CE analysis set. Clinical cure rates in both cIAI and HAP/VAP subgroups were consistent with the overall results, although 95% CIs were wide and the number of patients treated with colistin plus meropenem was small. Microbiological response rate was 71.7% for aztreonam-avibactam and 46.7% for colistin plus meropenem (microbiological ITT). Twenty-eight-day mortality was similar for aztreonam-avibactam (7.5%) and colistin plus meropenem (11.5%; ITT). Proportions of patients with all-cause adverse events (AEs) and serious AEs were generally similar in both groups, with fewer treatment-related AEs for aztreonam-avibactam. CONCLUSIONS: This exploratory post hoc analysis provides further insights into the efficacy and safety of aztreonam-avibactam versus colistin plus meropenem in patients with cIAI or HAP/VAP who were critically ill. CLINICAL TRIAL REGISTRATION: NCT number: NCT03329092.

Schlagwörter

Stichwörter der Autor:innen

Aztreonam–avibactamCarbapenem-resistant EnterobacteralesColistinComplicated intra-abdominal infectionCritically illHospital-acquired pneumoniaREVISIT post hoc analysisVentilator-associated pneumonia

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Middle Wulumuqi Road, Shanghai, 200040, China.
  • The National Center for Antibiotic Resistance and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Virgen del Rocío University Hospital-IBiS, CIBERINFEC, Seville, Spain.
  • National and Kapodistrian University of Athens, Athens, Greece.
  • Infectious Diseases Institute, Rambam Health Care Campus and Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
  • Tianjin Union Medical Center, Tianjin, China.

Förderung

  • Federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Dev…
  • Innovative Medicines Initiative Joint Undertaking
  • European Union Seventh Framework Programme
  • Pfizer
  • European Federation of Pharmaceutical Industries and Associations [COMBACTE-CARE consortium]

Zitieren

APA

Yuan, J., Carmeli, Y., Cisneros, J. M., Daikos, G. L., Paul, M., Zhao, Y., Xu, J., Ma, Y., Xu, W., Wible, M., Leaney, J., Leister-Tebbe, H., Kamat, S., Mohamed, N., & Wang, M. (2026). Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-026-01477-3

Vancouver

Yuan J, Carmeli Y, Cisneros JM, Daikos GL, Paul M, Zhao Y, et al. Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study. Infectious Diseases and Therapy. 2026. doi:10.1007/s40121-026-01477-3

BibTeX
@article{Yuan2026,
  author = {Yuan, Jinyi and Carmeli, Yehuda and Cisneros, José Miguel and Daikos, George L and Paul, Mical and Zhao, Yongjie and Xu, Jinfu and Ma, Ying and Xu, Wenjuan and Wible, Michele and Leaney, Joanne and Leister-Tebbe, Heidi and Kamat, Shweta and Mohamed, Naglaa and Wang, Minggui},
  title = {Aztreonam–Avibactam for Patients Who are Critically Ill with Gram-Negative Bacterial Infections: Comparison with Colistin Plus Meropenem Subgroup from the Phase 3 REVISIT Study},
  journal = {Infectious Diseases and Therapy},
  year = {2026},
  doi = {10.1007/s40121-026-01477-3}
}
Kostenlos starten →